The enzyme preparation—typically comprising a metalloproteinase/endopeptidase complex obtained from Bacillus subtilis fermentation with declared activity of ≥500,000 U/g (azocasein substrate, pH 7.0, 50°C)—is deployed in atmospheric-pressure bone broth reactors operating at 55–60°C with pH maintained between 6.5 and 7.0 via disodium phosphate buffer dosing. Hydrolysis is terminated by thermal denaturation at 90°C for 15 minutes, at which point soluble protein yield from crushed chicken frames (mean particle size 8–15 mm) rises from 3.8–4.2% (untreated thermal extraction only) to 12–15% (w/w, dry bone basis) as determined by Kjeldahl nitrogen per AOAC 984.13. The reaction is conducted in continuous stirred-tank reactors (CSTR) with working volumes of 5,000–20,000 L and agitation at 35–45 rpm using anchor-type impellers, followed by decanting centrifugation (3,000×g, 10 min) and 150 µm rotary drum filtration. Compliance for the resulting bone broth as a commercial food ingredient is anchored to FDA 21 CFR 184.1027 for GRAS-status enzyme preparations, with finished product microbiological thresholds defined by ISO 7218:2016 (generic Salmonella, Listeria monocytogenes, and Enterobacteriaceae enumeration), and thermal process validation per 21 CFR 113.40 when retorted in hermetically sealed containers. The formulation addition ratio for this enzyme is 0.1–0.3% by weight of crushed bone mass (equivalent to 1–3 g/kg raw bone), with the lower bound applied when adherent meat tissue exceeds 30% of total input mass to avoid excessive free glutamate accumulation. Downstream production sequence: mechanical bone crushing through a 10 mm plate grinder → slurry preparation at 1:1.2 bone-to-water ratio → pH adjustment with 0.5 M Na₂HPO₄ → enzyme dosing into CSTR → 2–4 hour hydrolysis under agitation → thermal inactivation at 90°C → two-stage centrifugation (disc-stack at 7,200 rpm followed by decanter) → plate heat exchanger cooling to 4°C → retort sterilization at 121°C for 45–60 min in stand-up pouches. Terminal product types include 500 mL–1 L retorted liquid bone broth pouches for retail bone broth beverages, 20 L bag-in-box culinary broths for HORECA kitchens, and aseptic 1,000 L bulk totes for secondary sauce manufacturers requiring clean-label liquid bases.

What Restricts Free Amino Acid Liberation in High-Brix Concentrated Chicken Paste?

Concentrated chicken broth paste operations encounter a specific kinetic limitation: as soluble solids rise above 25° Brix during vacuum concentration, the mean molecular weight of residual unhydrolyzed peptides increasingly resists further enzymatic attack due to steric hindrance from dissolved sugars and reduced water activity below 0.85. Trials conducted on 5,000 L pilot batches indicate that dosing this enzyme at 0.15–0.25% (w/w of raw bone input) prior to concentration yields a final paste with free amino nitrogen (FAN) of 1.8–2.4 g N/100 g dry matter, compared to 0.7–1.1 g N/100 g for purely thermal extraction under identical time-temperature profiles. The enzymatic reaction is executed for 3–4 hours at 58°C, pH 6.8, after which the slurry proceeds to a falling-film evaporator operating at 65–75°C under 60–80 kPa vacuum, concentrating from 6–8° Brix to 38–42° Brix. At this solids level, the viscosity range of 2,500–6,000 mPa·s at 40°C (Brookfield rotational viscometer, spindle No. 4, 20 rpm) sustains pumpability for volumetric filling into squeeze tubes or rigid tubs without stringing or tailing defects at line speeds exceeding 120 containers/min. Industry compliance anchors include EU Regulation (EC) No 1332/2008 Article 6 regarding enzyme preparation labeling and absence of viable production organism DNA in the final concentrate, and BRCGS Food Safety Standard Issue 9 clause 5.4.1 for process validation under high-solids thermal processing with documented hold-point deviation protocols. The terminal product categories comprise 1 kg polypropylene tubs of chicken broth paste for foodservice soup kettles requiring 1:8 reconstitution ratios, 250 g laminated squeeze tubes for retail stir-fry sauce bases with declared FAN content ≥2.0 g/100 g, and 10 kg bulk bag-in-box concentrates destined for co-manufactured pasta sauce production where the paste substitutes partially for sodium-reduced flavor systems.

Spray-dried chicken bone broth powder integrates the enzyme as a viscosity-reduction and solubility-enhancement step prior to atomization. A formulation addition of 0.20–0.35% enzyme by weight of deboned chicken back and neck raw material (pre-ground to 5 mm) is maintained for 2.5–3.5 hours at 57°C, pH 6.5, releasing soluble peptides with a degree of hydrolysis (DH) of 15–22% as quantified by the OPA (o-phthaldialdehyde) spectrophotometric method at 340 nm against L-serine calibration. After centrifugal clarification and 200 µm screening, the clarified liquor (18–22% total solids) is homogenized at 150/50 bar in a two-stage valve homogenizer and fed to a spray dryer operating with inlet air temperature 180–200°C, outlet air temperature 85–95°C, and pressure nozzle atomization at 120–150 bar, producing powder with moisture content 3.5–4.5% (w/w) and bulk density 0.45–0.55 g/mL. The enzymatic pre-treatment maintains feed viscosity below 150 mPa·s at 55°C, which prevents nozzle bearding and cyclone wall deposition that otherwise reduce recovery efficiency below 85%. Compliance for exported seasoning powders references Codex Alimentarius General Standard for Food Additives (GSFA), CX/FA 17/49/9, for enzyme carry-over status and ISO 22000:2018 clause 8.5.2 for allergen control in shared dry-blending facilities where soy lecithin (2% w/w as anti-caking agent) is introduced post-drying. Terminal product forms include 20–25 kg multiwall paper bags with HDPE inner liners for industrial seasoning compounders, 1 kg retail jars blended with sodium chloride and dehydrated vegetable flakes at 15–20% inclusion, and agglomerated instant soup sachet powders where the hydrolyzed bone powder constitutes 35–45% of the dry blend with sodium carbonate as effervescent carrier.

Collagen Polypeptide Molecular Weight Distribution After Chicken Sternum Demineralization

Demineralized chicken bone matrix, obtained by treatment of crushed sternum and femur segments with 0.5 M HCl at 4°C for 12 hours followed by washing to conductivity <50 µS/cm, provides a substrate in which the enzyme's endopeptidase activity liberates collagen fragments with molecular weight distributions dependent on reaction time and enzyme-to-substrate ratio. At an enzyme addition rate of 0.30–0.50% (w/w of demineralized bone solids) and reaction conditions of 55°C for 4–6 hours at pH 7.0–7.5, the resulting hydrolysate exhibits a gel permeation chromatography (GPC) profile with major component at 1,000–5,000 Da (constituting 55–65% of total peak area) and minor fraction below 500 Da (15–20%). This molecular weight window is confirmed against calibration standards including bovine serum albumin (66 kDa), cytochrome C (12.4 kDa), and vitamin B₁₂ (1.35 kDa), with column void volume corrected using blue dextran. The complete process sequence includes: demineralization in high-density polyethylene tanks → neutralization with 1 M NaOH to pH 7.0 → enzyme addition in a jacketed stirred reactor with retractable pH probe and data-logged temperature deviation alarms → inactivation at 85°C for 20 min → activated carbon decolorization (2% w/w, 60 min, 75°C) → diatomaceous earth pre-coat filtration on plate-and-frame press at 3 bar maximum differential pressure → ultrafiltration via 10 kDa polyethersulfone membrane in crossflow configuration at 3 bar transmembrane pressure and 45°C → freeze drying (−40°C shelf, 0.2 mbar) or low-temperature spray drying with inlet 160°C. Regulatory compliance for collagen hydrolysate derived from animal by-products includes ISO 22442-1:2020 clause 5.3 for sourcing from certified healthy slaughtered animals and EU Regulation (EC) No 1069/2009 Category 3 material verification with accompanying commercial documentation. Terminal products are 100-mesh freeze-dried collagen peptide powders for functional beverage formulations requiring solubility above 98% at 20°C, aqueous 30% w/w collagen solutions in 200 kg drums for cosmeceutical intermediate blending, and pharmaceutical-grade low-bloom bone-derived gelatin substitute pellets with gel strength below 50 bloom for capsule shell compatibility testing.

Instant noodle liquid seasoning sachet production integrates the enzyme-treated broth as a primary flavor foundation within a compressed process window of 90–120 minutes, using 0.10–0.20% enzyme (w/w of pre-cooked bone residue) at 60°C before blending with sodium glutamate (8–12% w/w), disodium inosinate (0.3–0.5% w/w), garlic oil (1.5–2.0% w/w), and xanthan gum (0.15% w/w as emulsion stabilizer). The perfused hydrolysate is homogenized at 200 bar and pasteurized at 92°C for 30 seconds via tubular heat exchanger, then aseptically dispensed into 35–50 mL multilayer sachets at a fill viscosity of 250–800 mPa·s to prevent seal contamination during high-speed vertical form-fill-seal operation. The finished seasoning complies with FDA 21 CFR 182.1 for GRAS status of hydrolyzed protein preparations and requires mandatory allergen labeling for soy sauce co-ingredients per 21 CFR 101.8 when blended formulations are exported to North American markets. Terminal sachet configurations are designated for instant cup noodles with 45 g liquid seasoning fill, pouched ramen kits with 32 g sachet alongside dehydrated vegetable packets, and microwaveable rice topping applications where the seasoning is co-packed with retort rice pouches.

When Enzymatic Hydrolysate Substitutes for Yeast Extract in Retort-Stable Pet Gravy Systems

Retort-stable pet food gravies manufactured with mechanically deboned chicken frames must sustain emulsion stability through 121°C thermal processing without phase separation, a requirement that becomes acute when yeast extract (typically 2.0–4.0% w/w) is replaced by enzymatically derived broth concentrate at 12–18% solids. The enzyme is applied at 0.05–0.15% (w/w of raw bone mass) during a 60–90 minute hydrolysis at 58°C, generating short-chain peptides that reduce interfacial tension at the oil-water boundary of the gravy emulsion as evidenced by a 22% reduction in creaming index after 7-day accelerated storage at 40°C relative to controls without enzymatic modification. The process integration point is post-meat-slurry heating and pre-canning, where the hydrolysate is combined with modified tapioca starch (3.5% w/w), kappa-carrageenan (0.3% w/w), and sodium tripolyphosphate (0.5% w/w) in a vacuum emulsifier operating at 4,000 rpm for 20 min under −0.5 bar, before filling into 350 g aluminum cans and retorting at 121°C for 55 min with forced-air cooling to 38°C core temperature. Regulatory alignment includes AAFCO Official Publication Chapter 6 for pet food ingredient definitions and nutrient profile adequacy, FDA 21 CFR 507 Subpart B for preventive controls in animal food facilities with written hazard analysis, and EU Regulation (EC) No 1069/2009 Article 14 for use of Category 3 animal by-products in pet food with documented traceability to slaughterhouse of origin. Terminal products are 350 g retorted canned pet food gravy with declared crude protein ≥6.0%, 85 g foil pouches of cat food toppers with palatability enhancement from hydrolyzed peptide fractions, and refrigerated 500 g tubs of fresh pet bone broth requiring cold-chain distribution below 4°C and 21-day shelf-life validation per ISO 17468:2016.